New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:34 EDTBLUE, TGT, WMB, BHP, WFT, NOK, AMT, EOG, COV, FIO, IGT, CCL, MDTOptions expected to be active
Options expected to be active: WFT MDT COV BHP CCL EOG WMB IGT AMT TGT FIO NOK BLUE
News For WFT;MDT;COV;BHP;CCL;EOG;WMB;IGT;AMT;TGT;FIO;NOK;BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 22, 2015
05:45 EDTNOKNokia reinstated with a Buy at Goldman
January 21, 2015
18:27 EDTCOVOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
18:06 EDTMDT, COVS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
17:18 EDTCOVEndo to replace Covidien in S&P 500 as of 1/26 close
15:27 EDTCOVNotable companies reporting before tomorrow's open
Subscribe for More Information
12:27 EDTBLUEbluebird bio price target raised to $146 from $94 at Wedbush
Subscribe for More Information
10:01 EDTWFTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:12 EDTWFTWeatherford downgraded to Neutral from Buy at BofA/Merrill
January 20, 2015
18:21 EDTBHPBHP Billiton provides operational update
Group production increased by 9% during the December 2014 half year with records achieved for eight operations and five commodities. Production guidance remains unchanged and we are on track to deliver Group production growth of 16% over the two years to the end of the 2015 financial year. Metallurgical coal production increased by 21% to 26 Mt in the December 2014 half year as Queensland Coal and Illawarra Coal both achieved record half year volumes. Western Australia Iron Ore production increased by 15% to a record of 124 Mt (100% basis) in the December 2014 half year as the ramp-up of Jimblebar continued and we improved the availability, utilisation and rate of our integrated supply chain. Petroleum production increased by 9% to a record 131 MMboe in the December 2014 half year supported by a 71% increase in Onshore US liquids volumes to 24.4 MMboe. Copper production decreased by 2% to 813 kt as strong underlying operating performance across the business was offset by lower grades at Antamina. Record manganese ore and alumina production was underpinned by strong performances at both Hotazel and the Alumar refinery.
18:19 EDTBHPBHP Billiton to reduce U.S. rigs by about 40% by end of current fiscal year
Subscribe for More Information
13:21 EDTBLUECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
09:44 EDTTGTSupreme Court denies appeal of 'swipe fee' ruling, Reuters reports
Subscribe for More Information
06:51 EDTBHPBHP Billiton upgraded to Overweight from Neutral at HSBC
January 16, 2015
16:36 EDTTGTMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
13:39 EDTBHPBHP Billiton upgraded to Buy from Hold at Canaccord
Subscribe for More Information
10:27 EDTIGTOptions with increasing implied volatility
Subscribe for More Information
10:06 EDTAMTBofA/Merrill real estate analysts to hold an analyst/industry conference call
U.S. Real Estate Analyst Spector, along with EMEA Real State Analyst Bessell, HK/China Real Estate Analyst Ngai and ASEAN Real Estate Analyst Chua, discuss key trends in Global Property/Real Estate in 2015 on an Analyst/Industry conference call to be held on January 20 at 8 am.
10:01 EDTTGTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:55 EDTTGTChildren's Place Carter's may have opportunity from Target move, say Oppenheimer
Subscribe for More Information
07:23 EDTTGTTarget upgraded at BofA/Merrill
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use